References
- Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909–3918.
- American Cancer Society. What are the key statistics about non-Hodgkin lymphoma? 2019; [cited 2019 Jan 28]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html
- American Cancer Society. American Cancer Society: cancer facts and figures. Atlanta (GA); [cited 2019 Jan 28]; 2017. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
- National Cancer Institute. Financial burden of cancer care; 2018; [cited 2019 Jan 28]. Available from: https://progressreport.cancer.gov/after/economic_burden
- Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–128.
- Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18:51.
- Barnett A, Birnbaum H, Cremieux P-Y, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care. 2000;6:1243–1251.
- Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47:1535–1544.
- Danese MD, Reyes CM, Gleeson ML, et al. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54:343.
- Griffiths RI, Gleeson ML, Mikhael J, et al. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:1.
- Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52:2117–2123.
- Meyer N, Song X, Gregory SA, et al. Treatment patterns, mortality, and health care utilization and costs in indolent non-Hodgkin lymphoma patients with relapsed or refractory disease. J Clin Oncol. 2014;32:e19557.
- Gleeson M, Carolina R, Danese M, et al. Cost of follicular lymphoma (FL) in Medicare patients. J Clin Oncol. 2008;26:6634–6634.
- Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93:296–305.
- Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
- National Cancer Institute. SEER-Medicare: SEER program & data. National Cancer Institute; 2017; [cited 2017 Nov 20]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/program.html
- National Cancer Institute. Overview of the SEER program; [cited 2017 Nov 20]. Available from: https://seer.cancer.gov/about/overview.html
- US Department of Labor BoLS. Measuring price change for medical care in the CPI; 2010; [cited 2017 Nov 20]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm
- Davidoff AJ, Zuckerman IH, Pandya N, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and d outcomes. J Geriatr Oncol. 2013;4:157–165.
- Glick HA, Doshi JA, Sonnad SS, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2014.
- Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87:329–343.
- Wijeysundera HC, Wang X, Tomlinson G, et al. Techniques for estimating health care costs with censored data: an overview for the health services researcher. ClinicoEconom Outcomes Res: CEOR. 2012;4:145.
- Onukwugha E, Bergtold J, Jain R. A primer on marginal effects—part II: health services research applications. PharmacoEconomics. 2015;33:97–103.
- Greene WH. Econometric analysis. 7th ed. Upper Saddle River: Prentice Hall; 2012.
- Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
- Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood. 2016;127:2804–2808.
- Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419–1432.
- Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol. 2006;17:920–927.
- Shustik J, Quinn M, Connors JM, et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2011;22:1164–1169.
- Yabroff KR, Dowling EC, Guy GP, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259–267.